<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060172</url>
  </required_header>
  <id_info>
    <org_study_id>NST-01-2020-EU</org_study_id>
    <nct_id>NCT05060172</nct_id>
  </id_info>
  <brief_title>A Clinical Study for the Development and Validation of Bloomlife Non-Stress Test (NST)</brief_title>
  <acronym>NST</acronym>
  <official_title>A Cross-sectional, Interventional, Single-arm Clinical Study for the Development and Validation of Bloomlife Non-Stress Test (NST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bloom Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bloom Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bloomlife has developed a wearable system (Bloomlife NST) that can allow fetal monitoring to&#xD;
      be conveniently performed in healthcare settings under supervision of a healthcare&#xD;
      professional.&#xD;
&#xD;
      Bloomlife NST is a non-invasive, wireless, external monitoring system used to measure fetal&#xD;
      heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing&#xD;
      on pregnant women with a singleton pregnancy.&#xD;
&#xD;
      The purpose of this study is to validate that the Bloomlife NST is equivalent to clinical&#xD;
      standard-of-care for routine non-stress test (NST) performed at the hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extent of agreement between Bloomlife NST and CTG in fetal heart rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Bland-Altman analysis, based on a 95% limits of agreement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of agreement between Bloomlife NST and CTG in maternal heart rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Bland-Altman analysis, based on a 95% limits of agreement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of agreement between Bloomlife NST and CTG in detected contractions (based on expert annotations)</measure>
    <time_frame>1 hour</time_frame>
    <description>Bland-Altman analysis, based on a 95% limits of agreement</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fetal Monitoring</condition>
  <arm_group>
    <arm_group_label>Bloomlife NST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bloomlife NST</intervention_name>
    <description>Bloomlife NST is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.&#xD;
The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography and electrohysterography.</description>
    <arm_group_label>Bloomlife NST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman ≥ 18 years old&#xD;
&#xD;
          -  Gestational age ≥ 32 weeks and 0 days&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Ability to read and understand Dutch or English&#xD;
&#xD;
          -  Willingness to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Implanted pacemaker or any other implanted electrical device&#xD;
&#xD;
          -  Plurality higher than 1&#xD;
&#xD;
          -  History of allergies to skin adhesives&#xD;
&#xD;
          -  Contraindication to the use of the CTG&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried Gyselaers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Rossetti</last_name>
    <phone>0483653848</phone>
    <phone_ext>+32</phone_ext>
    <email>elisa@bloom-life.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien Penders</last_name>
    <phone>4156038067</phone>
    <phone_ext>+1</phone_ext>
    <email>julien@bloom-life.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne Marien, MS</last_name>
      <phone>089212032</phone>
      <phone_ext>+32</phone_ext>
      <email>Hanne.Marien@zol.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

